CORRECTION

Clarifications for Primary and Secondary Outcomes and Analyses: The Original Investigation "Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years: A Randomized Clinical Trial," was first published online on June 1, 2023, in JAMA Ophthalmology. Following that publication, JAMA Network editors have added clarifications to report the findings for the primary end point before the secondary end points per the trial statistical analysis plan (SAP). Per the prespecified SAP, the primary and all secondary end points comprise a fixed sequence set of end points to be tested in order. Secondary end points after the primary end point may be considered exploratory. The article with the clarification is now available online.

1. Zadnik K, Schulman E, Flitcroft I, et al; CHAMP Trial Group Investigators. Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial. JAMA Ophthalmol. Published online June 1, 2023. doi:10.1001/jamaophthalmol.2023.2097